Santarus Reaches New 52-Week High (SNTS)

NEW YORK ( TheStreet) -- Santarus (Nasdaq: SNTS) hit a new 52-week high Tuesday as it is currently trading at $6.97, above its previous 52-week high of $6.93 with 426,605 shares traded as of 3:50 p.m. ET. Average volume has been 520,800 shares over the past 30 days.

Santarus has a market cap of $429.6 million and is part of the health care sector and drugs industry. Shares are up 106.3% year to date as of the close of trading on Monday.

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company has a P/E ratio of 76.2, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Santarus as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full Santarus Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

If you liked this article you might like

Investors Expect too Much of Salix

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Santarus (SNTS): Heavy Pre-Market Activity

Salix Pharma to Acquire Santarus

Insider Trading Alert - Santarus And 4 Others Traded By Insiders